(NASDAQ: STOK) Stoke Therapeutics's forecast annual revenue growth rate of -26.62% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 117.31%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 22.77%.
Stoke Therapeutics's revenue in 2026 is $205,632,000.On average, 13 Wall Street analysts forecast STOK's revenue for 2026 to be $2,010,580,797, with the lowest STOK revenue forecast at $671,697,684, and the highest STOK revenue forecast at $4,198,110,525. On average, 10 Wall Street analysts forecast STOK's revenue for 2027 to be $3,796,862,546, with the lowest STOK revenue forecast at $1,981,508,168, and the highest STOK revenue forecast at $6,297,165,788.
In 2028, STOK is forecast to generate $4,420,239,121 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $7,976,409,998.